Physician profile
Joseph Patrick Lucas
NPI 1538118500
$3,807.10
in general payments reported to CMS, 2019-2025
20 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $143 · 2021: $54.13 · 2022: $344 · 2023: $1,248 · 2024: $432 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.33 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $547.49 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $545.95 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $417.52 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $344.75 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $277.56 | 2022-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $230.61 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $198.03 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $165.85 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $134.27 | 2022-2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $100.81 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $52.75 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $41.94 | 2024-2025 | Trintellix |
| Tris Pharma INC | $41.91 | 2024-2025 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $36.10 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.45 | 2024 | Perseris |
| Bausch Health US, LLC | $22.72 | 2024 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $17.66 | 2019 | |
| Almatica Pharma LLC | $17.14 | 2023 | Sertraline Hcl, Loreev Xr |
| Neos Therapeutics, LP | $15.26 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.